



Coverage, Billing, and Financial Assistance for Foundation Medicine Tests



Our billing and reimbursement support is designed to make comprehensive genomic profiling accessible to patients.

Our experience shows that:



Insurance Coverage

- All Foundation Medicine tests are covered for qualifying Medicare beneficiaries who meet clinical criteria.⁸⁻¹¹
- Qualifying Original Medicare[®] beneficiaries have no out-of-pocket costs for Foundation Medicine testing.
- Some commercial health plans such as Cigna and many BlueCross BlueShield plans offer coverage for Foundation Medicine's testing services. FoundationOne[®]Heme and FoundationOne[®]Liquid CDx tests have limited commercial health plan coverage at this time.

Billing Practices

- Foundation Medicine will make every attempt to support insurance coverage and payment for testing, which may include obtaining prior authorizations, billing the health plan for the test, and appealing denials with the patient's consent.
- Foundation Medicine will only bill patients after following the claims process for any amount indicated as the patient responsibility, which may include deductibles, co-insurances, copay, or non-covered charges.
- Foundation Medicine will attempt to reach out to any patient who may owe more than \$500.

Foundation Medicine Financial Assistance Program

Financial assistance is available for qualifying patients who have out-of-pocket costs associated with Foundation Medicine testing. Financial assistance is based on need and can be applied for at any point during the testing process.*

* Foundation Medicine's Financial Assistance Program is only available to patients whose tests were ordered within the United States and U.S. territories.

Pricing for Foundation Medicine's Tests

FOUNDATIONONE® CDx	\$5,800.00
FOUNDATIONONE® LIQUID CDx	
FOUNDATIONONE® HEME	
PD-L1 (Immunohistochemistry)	\$250.00

Questions

The Foundation Medicine team is here to help. If you or your patient has an Explanation of Benefits (EOB) or bill in hand and have any questions, please contact our billing department.

Call: 877.246.9204

Email: foundationmedicine@mylabbill.com

Fax: 440.528.6010

References

1. Data on file at Foundation Medicine
2. 61% of commercially insured patients and 90% of Medicare and Medicare Advantage patients paid \$0 for Foundation Medicine testing
3. Based on tests reported between January 1, 2019 and March 31, 2020. Data current as of June 16, 2020.
4. Includes FoundationOne®CDx, FoundationOne®Liquid, FoundationOne®Heme, and immunohistochemistry testing (IHC) performed at Foundation Medicine
5. Based on patient financial responsibility before taking into account any financial assistance awarded by Foundation Medicine's need-based financial assistance program
6. Based on settled claims (i.e., Foundation Medicine has exhausted its appeals and reimbursement efforts)
7. Based on 65% of commercially insured patients and 97% of Medicare/Medicare Advantage patients having or qualifying for a payment of \$100 or less
8. Medicare administered by federal government.
9. Medicare administered by private insurers.
10. For FoundationOne®CDx and FoundationOne®Liquid CDx, see "Decision for Next Generation Sequencing (NGS) for Medicare Beneficiaries with Advanced cancer - CAG-00450R." (See Appendix B)
11. For FoundationOne®Heme, see the "Local Coverage Determination (LCD): MoIDX: NEXT-GENERATION Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (L38047)"

FoundationOne Heme is a laboratory developed test and was developed and its performance characteristics determined by Foundation Medicine. It has not been cleared or approved by the U.S. Food and Drug Administration. For more information on this laboratory developed test please see the Technical Specifications at <http://foundationoneheme.com/>.

FoundationOne®CDx and FoundationOne®Liquid CDx are qualitative next-generation sequencing based *in vitro* diagnostic tests for advanced cancer patients with solid tumors and are for prescription use only. FoundationOne CDx utilizes FFPE tissue and analyzes 324 genes as well as genomic signatures. FoundationOne Liquid CDx analyzes 324 genes utilizing circulating cell-free DNA and is FDA-approved to report short variants in 311 genes. The tests are companion diagnostics to identify patients who may benefit from treatment with specific therapies in accordance with the therapeutic product labeling. Additional genomic findings may be reported and are not prescriptive or conclusive for labeled use of any specific therapeutic product. Use of the tests does not guarantee a patient will be matched to a treatment. A negative result does not rule out the presence of an alteration. Some patients may require a biopsy for testing with FoundationOne CDx when archival tissue is not available which may pose a risk. Patients who are tested with FoundationOne Liquid CDx and are negative for companion diagnostic mutations should be reflexed to tumor tissue testing and mutation status confirmed using an FDA-approved tumor tissue test, if feasible.

For the complete label, including companion diagnostic indications and important risk information, please visit <http://www.FICDxLabel.com> and <http://www.FILCDxLabel.com>.

